PMID- 21951293
OWN - NLM
STAT- MEDLINE
DCOM- 20120328
LR  - 20211025
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 67
IP  - 1
DP  - 2012 Jan
TI  - EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal 
      clinically important difference.
PG  - 99-106
LID - 10.1111/j.1398-9995.2011.02719.x [doi]
AB  - BACKGROUND:   Demonstration of adequate reliability and validity is sufficient 
      for concluding that an instrument is applicable for descriptive and predictive 
      purposes, but before we can confidently use an outcome measure in clinical 
      trials, the responsiveness (synonymous with sensitivity to change) and minimal 
      clinically important difference (MCID) should be known. With this study, we aimed 
      to assess responsiveness and MCID of four outcome measures used in atopic eczema: 
      the Severity Scoring of Atopic Dermatitis (SCORAD), the objective SCORAD, Eczema 
      Area and Severity Index (EASI), and the Patient-Oriented Eczema Measure (POEM). 
      METHODS:   Data of three randomized controlled trials were used. To demonstrate 
      responsiveness, we plotted receiver operating characteristic (ROC) curves. MCID 
      was estimated using mean change scores of patients that showed a relevant 
      improvement. Bland and Altman methods were used to quantify the limits of 
      agreement. RESULTS:   Area under the ROC curve for the SCORAD was 0.70 [95% 
      confidence interval (CI): 0.61-0.78], for the objective SCORAD, 0.73 (95% CI: 
      0.70-0.77), for the EASI, 0.67 (95% CI: 0.60-0.76), and for the POEM, 0.67 (95% 
      CI: 0.59-0.75). Scores above 0.70 represent a fair responsiveness. The MCID was 
      8.7 points for the SCORAD, 8.2 for the objective SCORAD, 6.6 for the EASI, and 
      3.4 for the POEM. CONCLUSION:   The objective SCORAD and SCORAD showed a fair 
      responsiveness. The MCIDs are an important prerequisite for the interpretation of 
      published eczema trials and for the planning/sample size estimation of future 
      trials.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Schram, M E
AU  - Schram ME
AD  - Department of Dermatology, Academic Medical Center, University of Amsterdam, the 
      Netherlands. M.E.Schram@amc.uva.nl
FAU - Spuls, Ph I
AU  - Spuls PI
FAU - Leeflang, M M G
AU  - Leeflang MM
FAU - Lindeboom, R
AU  - Lindeboom R
FAU - Bos, J D
AU  - Bos JD
FAU - Schmitt, J
AU  - Schmitt J
LA  - eng
PT  - Journal Article
DEP - 20110927
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Dermatitis, Atopic/*drug therapy
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - ROC Curve
MH  - Randomized Controlled Trials as Topic
MH  - *Reproducibility of Results
MH  - *Treatment Outcome
EDAT- 2011/09/29 06:00
MHDA- 2012/03/29 06:00
CRDT- 2011/09/29 06:00
PHST- 2011/09/29 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/03/29 06:00 [medline]
AID - 10.1111/j.1398-9995.2011.02719.x [doi]
PST - ppublish
SO  - Allergy. 2012 Jan;67(1):99-106. doi: 10.1111/j.1398-9995.2011.02719.x. Epub 2011 
      Sep 27.